De Motu Cordis (DMC) unveiled plans for the next stage of development with its contract development and manufacturing organization (CDMO) partner, Catalent, at Catalent's Boston, Morrisville and San Diego sites. These expansion plans encompass services from drug product manufacturing and device assembly through to commercial launch of DMC's product, DMC-IH1. DMC-IH1 is an inhaled epinephrine drug-device combination product being developed for the treatment of anaphylaxis using a dry powder inhaler (DPI).
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany
Catalent stockholders approve buyout by Novo Holdings
Catalent Stockholders Approve Transaction with Novo Holdings
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., which was recently acquired by Novo Holdings, have entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.
Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
FTC to review Novo Holdings` Catalent buyout for another month
Novo Nordisk parent refiles US application on Catalent deal
After Novo Holdings set the stage for a $16.5 billion buyout of contract manufacturing giant Catalent earlier this year, its parent company is giving antitrust officials more time for their review with one simple trick.